Loading…
← CockpitCompetitor Analysis › 688799.SS Hunan Warrant Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Hunan Warrant Pharmaceutical Co., Ltd. Class A688799.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Hunan maker of transdermal medicated patches and topical drugs sold through Chinese pharmacies.

≈ A small Chinese medicated-patch makerMomentum weak 29
Mkt cap
$725M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$23.3M
20-day average traded
Fwd P/E
47.6×
forward earnings
ROIC−WACC
-0.6 pp
WACC 6.0%
Hurdle
n/a
no reverse DCF
Next earnings
160 days
27 Apr 2027
Close · CNYCN¥38.16
1D-10.2%
1W-24.3%
1M-19.0%
3M-17.6%
6M-33.6%
YTD-20.0%
1Y-23.5%
ATR %8.8%
52w lowhigh41.5% off high

What Hunan Warrant Pharmaceutical does

Hunan maker of transdermal medicated patches and topical drugs sold through Chinese pharmacies.

In one line: A small Chinese medicated-patch maker.

Products and services

  • Medicated transdermal patches
  • Other topical drugs

Customers

  • Retail pharmacies
  • Hospitals

Where it sits in the supply chain

  • Pharmaceuticals
  • OTC/consumer health
  • Transdermal patches

What could go right

  • OTC pain-relief patch demand

What could go wrong

  • OTC price competition

Moat: narrow (brand). Established patch brand with pharmacy distribution, though a niche OTC category.

Headquarters: Changsha, Hunan, China · Employees: 1,291

Named competitors

Hunan Warrant Pharmaceutical at a glance

Size Hunan Warrant Pharmaceutical (688799.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $725M, the 2818th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥38.16 on 18 Nov 2026.

Performance Over six months the shares fell 33.6%, against -7.0% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue fell 2.6% over the last twelve months (peer median +0.7%); the operating margin is 9.5% (peer median 9.7%).

Valuation It trades at 47.6× forward earnings against a peer median of 13.7× (most expensive of 8).

Capital Return on invested capital runs 0.6 points below its cost of capital (6.0% WACC).

Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 94688799.SS 67
Six months, rebased to 100: Hunan Warrant Pharmaceutical against the median of its 20 peers (local-currency closes).

Hunan Warrant Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.38BCN¥1.50BCN¥1.39BCN¥1.41BCN¥1.28B
Revenue growth—+8%-2%+10%—
Gross profitCN¥823MCN¥868MCN¥820MCN¥881MCN¥844M
EBITDAn/aCN¥216MCN¥205MCN¥265MCN¥216M
Net incomeCN¥114MCN¥238MCN¥164MCN¥211MCN¥183M
Free cash flow-CN¥182M-CN¥202M-CN¥91.4MCN¥119MCN¥36.5M
Capital expenditureCN¥577MCN¥520MCN¥234MCN¥106MCN¥132M
Total debtCN¥860MCN¥507MCN¥165MCN¥24.2MCN¥13.1M

Quarterly statements and history in the cockpit →

Hunan Warrant Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%-10%0%+10%600530688566SGMT6039980570453421863007056004796008292171002907NVCT00242449850009153001LXRX600351688799.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Hunan Warrant Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%20×40×688566603998453421863007054985000915688799.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hunan Warrant Pharmaceutical is the large dot.

Hunan Warrant Pharmaceutical competitors and peer comparison

Head to head with its named competitors (688799.SS vs 600285.SS vs 603858.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Hunan Warrant Pharmaceutical 688799.SS$725M-34%-3%9%47.6×n/a
Henan Lingrui Pharmaceutial 600285.SS$2.04B+9%+5%22%15.9×-4.7%
Shandong Buchang Pharmaceuticals 603858.SS$2.25B-7%+4%10%n/a-2.5%

How Hunan Warrant Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hunan Warrant Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure688799.SSPeer medianRank in peer set
1-month return-19.0%-3.8%3rd lowest of 21
6-month return-33.6%-7.0%2nd lowest of 21
Distance from 52-week high-41.5%-32.6%7th lowest of 21
Revenue growth (TTM)-2.6%+0.7%8th lowest of 19
Operating margin9.5%9.7%9th lowest of 19
Forward P/E47.6×13.7×most expensive of 8
ROIC minus cost of capital-0.6 pp+1.2 pp6th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Hunan Warrant Pharmaceutical 688799.SSChina$725M-34%-3%9%47.6×n/an/a
Shanghai Jiaoda Onlly 600530.SSChina$726M-25%-2%-2%n/a42.7%-0.9%
Jiangsu Jibeier Pharmaceutical 688566.SSChina$727M-9%+8%26%11.2×5.9%+11.3%
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a
Hunan Fangsheng Pharmaceutical 603998.SSChina$719M-1%+12%20%13.7×-4.8%+6.4%
China Traditional Chinese Medicine 0570.HKHong Kong$716M-31%-16%0%n/an/an/a
Mochida Pharmaceutical 4534.TJapan$714M-3%+16%10%16.1×n/an/a
Luye Pharma 2186.HKHong Kong$736M-32%+3%18%7.1×-11.8%+1.9%
Hunan Jiudian Pharmaceutical 300705.SZChina$738M-20%-5%13%16.7×-2.0%+26.1%
Zhuzhou Qianjin Pharmaceutical 600479.SSChina$746M-3%+4%11%n/a-2.1%0.0%
HPGC Renmintongtai Pharmaceutical 600829.SSChina$701M-6%+4%2%n/a4.0%+5.3%
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%n/an/an/a
Chongqing Pharscin Pharmaceutical 002907.SZChina$752M-7%+8%10%n/a9.4%-1.4%
Nuvectis Pharma NVCTUnited States$698M+91%n/an/an/an/an/a
Guizhou Bailing Group Pharmaceutical 002424.SZChina$755M-20%-25%2%n/a13.5%-0.2%
Earth 4985.TJapan$687M+7%+4%4%18.0×-1.6%-1.8%
Shandong Wit Dyne Health 000915.SZChina$687M-31%-36%36%9.1×n/an/a
Katakura Industries 3001.TJapan$765M+40%-2%15%n/a0.3%+0.5%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%n/an/an/a
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%n/a-3.8%-0.8%
Yabao Pharmaceutical 600351.SSChina$678M0%-3%16%n/a-8.3%-2.8%

Questions

Who are Hunan Warrant Pharmaceutical's main competitors?
Named competitors: Henan Lingrui Pharmaceutical (600285.SS), Buchang Pharmaceutical (603858.SS). The cockpit's measured peer set (industry) also includes Shanghai Jiaoda Onlly (600530.SS), Jiangsu Jibeier Pharmaceutical (688566.SS), Sagimet Biosciences (SGMT), Hunan Fangsheng Pharmaceutical (603998.SS), China Traditional Chinese Medicine (0570.HK), Mochida Pharmaceutical (4534.T).
Is Hunan Warrant Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 47.6× against a peer median of 13.7×, most expensive of 8 in its peer set.
How has Hunan Warrant Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -33.6% against -7.0% for the median peer; over one year -23.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.